The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease

[1]  A. Rico,et al.  Frizzled related protein deficiency impairs muscle strength, gait and calpain 3 levels , 2020, Orphanet Journal of Rare Diseases.

[2]  Y. Chien,et al.  GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry , 2019, Human mutation.

[3]  M. Hegde,et al.  Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients , 2018, Annals of clinical and translational neurology.

[4]  E. Zanoteli,et al.  Clinical Variability in 2 Siblings With Late-Onset Pompe Disease. , 2018, Journal of Clinical Neuromuscular Disease.

[5]  D. MacArthur,et al.  Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness , 2018, Skeletal Muscle.

[6]  G. Comi,et al.  Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease , 2018, Neuromuscular Disorders.

[7]  Bjarne Udd,et al.  229th ENMC international workshop: Limb girdle muscular dystrophies – Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017 , 2018, Neuromuscular Disorders.

[8]  D. MacArthur,et al.  Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness , 2017, Orphanet Journal of Rare Diseases.

[9]  C. Harding,et al.  Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease , 2017, American journal of medical genetics. Part A.

[10]  W. Hwu,et al.  Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum , 2017, Pediatrics.

[11]  R. Giugliani,et al.  Newborn Screening for Pompe Disease , 2017, Pediatrics.

[12]  V. D’Almeida,et al.  Late-onset Pompe disease: what is the prevalence of limb-girdle muscular weakness presentation? , 2017, Arquivos de Neuro-Psiquiatria.

[13]  H. Lv,et al.  Mutational spectrum of Chinese LGMD patients by targeted next-generation sequencing , 2017, PLoS ONE.

[14]  K. Stehlikova,et al.  Muscular dystrophies and myopathies: the spectrum of mutated genes in the Czech Republic , 2017, Clinical genetics.

[15]  A. Alazami,et al.  A first-line diagnostic assay for limb-girdle muscular dystrophy and other myopathies , 2016, Human Genomics.

[16]  D. MacArthur,et al.  The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States , 2016, Journal of Human Genetics.

[17]  I. Nishino,et al.  Targeted massively parallel sequencing and histological assessment of skeletal muscles for the molecular diagnosis of inherited muscle disorders , 2016, Journal of Medical Genetics.

[18]  B. Schlotter-Weigel,et al.  Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness , 2016, Neurology.

[19]  L. Wilkins,et al.  The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients , 2016, Neurology.

[20]  C. Angelini,et al.  Next generation sequencing detection of late onset pompe disease , 2016, Muscle & nerve.

[21]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[22]  R. Lachmann,et al.  Childhood Pompe disease: clinical spectrum and genotype in 31 patients , 2016, Orphanet Journal of Rare Diseases.

[23]  Sung Im Cho,et al.  Clinical applications of next‐generation sequencing‐based gene panel in patients with muscular dystrophy: Korean experience , 2016, Clinical genetics.

[24]  B. Schoser,et al.  Utility of a next-generation sequencing-based gene panel investigation in German patients with genetically unclassified limb-girdle muscular dystrophy , 2016, Journal of Neurology.

[25]  B. Udd,et al.  Targeted next-generation sequencing assay for detection of mutations in primary myopathies , 2016, Neuromuscular Disorders.

[26]  P. Jacques,et al.  Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing , 2016, Orphanet Journal of Rare Diseases.

[27]  D. MacArthur,et al.  Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned. , 2015, JAMA neurology.

[28]  P. Narayanaswami.  Dismantling Limb-Girdle Muscular Dystrophy: The Role of Whole-Exome Sequencing. , 2015, JAMA neurology.

[29]  L. Cui,et al.  A comprehensive genetic diagnosis of Chinese muscular dystrophy and congenital myopathy patients by targeted next-generation sequencing , 2015, Neuromuscular Disorders.

[30]  Z. Lukacs,et al.  Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort , 2015, Neuromuscular Disorders.

[31]  Saudi Mendeliome Group.  Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases , 2015, Genome Biology.

[32]  Mohammed Alhashem,et al.  Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases , 2015, Genome Biology.

[33]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[34]  Lora J. H. Bean,et al.  A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield , 2015, Annals of neurology.

[35]  S. Kiuru-Enari,et al.  Screening for late-onset Pompe disease in Finland , 2014, Neuromuscular Disorders.

[36]  R. Griggs,et al.  Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies , 2014, Neurology.

[37]  Yuan Xue,et al.  Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing , 2014, Genetics in Medicine.

[38]  G. Comi,et al.  MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples , 2014, Acta neuropathologica communications.

[39]  V. Nigro,et al.  Genetic basis of limb-girdle muscular dystrophies: the 2014 update , 2014, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[40]  F. Tsai,et al.  Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[41]  Xin-mei Jiang,et al.  Limb-girdle muscular dystrophies: Where next after six decades from the first proposal (Review) , 2014, Molecular medicine reports.

[42]  M. Kruijshaar,et al.  Phenotypical variation within 22 families with Pompe disease , 2013, Orphanet Journal of Rare Diseases.

[43]  J. Vissing,et al.  Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. , 2013, Molecular genetics and metabolism.

[44]  Lora J. H. Bean,et al.  Molecular diagnostic testing for congenital disorders of glycosylation (CDG): detection rate for single gene testing and next generation sequencing panel testing. , 2013, Molecular genetics and metabolism.

[45]  Heidi L. Rehm,et al.  Disease-targeted sequencing: a cornerstone in the clinic , 2013, Nature Reviews Genetics.

[46]  Madhuri Hegde,et al.  Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations , 2013, BMC Genetics.

[47]  D. Güngör,et al.  How to describe the clinical spectrum in Pompe disease? , 2013, American journal of medical genetics. Part A.

[48]  C. Alexander Valencia,et al.  Comprehensive Mutation Analysis for Congenital Muscular Dystrophy: A Clinical PCR-Based Enrichment and Next-Generation Sequencing Panel , 2013, PloS one.

[49]  P. Kang,et al.  Update on the genetics of limb girdle muscular dystrophy. , 2012, Seminars in pediatric neurology.

[50]  Lan-Fang Zhou,et al.  The diagnostic utility of a commercial limb-girdle muscular dystrophy gene test panel. , 2012, Journal of clinical neuromuscular disease.

[51]  Shashikant Kulkarni,et al.  Assuring the quality of next-generation sequencing in clinical laboratory practice , 2012, Nature Biotechnology.

[52]  E. Hoffman,et al.  Limb-Girdle Muscular Dystrophy Overview , 2012 .

[53]  M. Hegde,et al.  Assessment of target enrichment platforms using massively parallel sequencing for the mutation detection for congenital muscular dystrophy. , 2012, The Journal of molecular diagnostics : JMD.

[54]  N. Laing.  Genetics of neuromuscular disorders , 2012, Critical reviews in clinical laboratory sciences.

[55]  Thomas P. Mechtler,et al.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria , 2012, The Lancet.

[56]  Madhuri R Hegde,et al.  Targeted polymerase chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation , 2011, Genetics in Medicine.

[57]  J. Jaeken,et al.  Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study , 2010, Neuromuscular Disorders.

[58]  E. Hoffman,et al.  Limb–Girdle and Congenital Muscular Dystrophies: Current Diagnostics, Management, and Emerging Technologies , 2010, Current neurology and neuroscience reports.

[59]  A. Pestronk,et al.  A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.

[60]  J. Clancy,et al.  Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.

[61]  A. Reuser,et al.  Pompe's disease , 2008, The Lancet.

[62]  P. Doorn,et al.  Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease , 2008, Neuromuscular Disorders.

[63]  W. Hwu,et al.  Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease , 2007 .

[64]  G. Herman,et al.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[65]  W. Hop,et al.  Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. , 2005, Brain : a journal of neurology.

[66]  T. Voit,et al.  Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. , 2005, Neuropediatrics.

[67]  T. Voit,et al.  Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial , 2005, Neuromuscular Disorders.

[68]  M. Zatz,et al.  The 10 autosomal recessive limb-girdle muscular dystrophies , 2003, Neuromuscular Disorders.

[69]  WMADo Helsinki.  World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. , 2000, Nursing ethics.

[70]  A. Vulto,et al.  Recombinant human α-glucosidase from rabbit milk in Pompe patients , 2000, The Lancet.

[71]  L. Sandkuijl,et al.  Glycogen Storage Disease Type II: Birth Prevalence Agrees with Predicted Genotype Frequency , 2000, Public Health Genomics.

[72]  W. Rom,et al.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. , 1998, American journal of medical genetics.

[73]  A. Hamed,et al.  Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis , 2016, Journal of Neurology.

[74]  Carlene Campbell,et al.  Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. , 2015, The Journal of pediatrics.

[75]  P. Narayanaswami,et al.  Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. , 2015, Neurology.

[76]  F. Glocker,et al.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial , 2009, Journal of Neurology.

[77]  T. Ichida,et al.  World Medical Association declaration of Helsinki , 2008, Gastroenterologia Japonica.

[78]  B. Byrne,et al.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. , 2007, Neurology.

[79]  A. Reuser,et al.  Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. , 2000, Lancet.

[80]  K. Bushby,et al.  The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. , 1999, Human molecular genetics.

[81]  M. Hegde,et al.  Targeted PCR-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation (CDG) , 2022 .